Introduction {#Sec1}
============

Ulcerative colitis (UC), a chronic inflammatory bowel disease, is stratified by the extent of colonic involvement: ulcerative proctitis (UP), ulcerative proctosigmoiditis (UPS), left-sided, extensive, and pancolitis \[[@CR1]--[@CR3]\]. In UP, inflammation is limited to the rectum (i.e., distal to the rectosigmoid junction), while inflammation in UPS, considered a form of distal UC, is characterized by rectal and sigmoid inflammation without involvement of the descending colon \[[@CR2]--[@CR4]\]. Approximately 46 % of patients with UC have UP or UPS \[[@CR4], [@CR5]\]. Clinical symptoms of UC include rectal bleeding, diarrhea, urgency, tenesmus, and abdominal pain \[[@CR1]\], with some patients with limited distal UC also experiencing paradoxical constipation \[[@CR6]\].

First-line therapy for induction of remission is rectal 5-aminosalicylate (5-ASA) formulations (i.e., suppository, foam, or enema) for patients with UP, and rectal 5-ASA alone or in combination with oral 5-ASA for patients with more proximal left-sided disease involvement \[[@CR7]--[@CR10]\]. 5-ASA preparations are slow to act, and for patients with more significant symptoms, rectally administered corticosteroids are considered second-line therapy for induction of more rapid remission in patients with UP or UPS. However, conventional corticosteroids are associated with undesirable systemic effects, which limit their use.

Rectal therapies include suppositories, enemas, or foam preparations. Suppositories are not only difficult for some patients to administer \[[@CR11]\], but the use of suppositories is restricted by their limited proximal distribution within the rectum \[[@CR12]\], in contrast to foam preparations, which can spread to the descending colon \[[@CR13]\]. Foam preparations provide greater retention and more uniform distribution within the distal colon and rectum compared with enema preparations \[[@CR14]--[@CR16]\]. In addition, rectal foam preparations are generally preferred by patients over rectal enema formulations \[[@CR17]\].

Budesonide foam, a rectally administered second-generation corticosteroid, has minimal systemic effects due to extensive first-pass metabolism in the liver after absorption. Budesonide foam was efficacious for the treatment of active UP and UPS in four phase III studies, including a randomized, active-controlled, multicenter study \[[@CR18]\], and a randomized, double-blind, double-dummy, multicenter study \[[@CR17]\]. Also, patients successfully completing two identically designed, placebo-controlled, phase III trials \[[@CR19]\] were permitted to continue in a phase III, open-label extension study and receive repeat cycles of budesonide foam for recurrent flares. In this integrated analysis of safety, data from these five phase III studies were pooled for a detailed evaluation of the safety of budesonide foam. In addition, population pharmacokinetics were assessed to characterize the systemic exposure parameters of budesonide foam by pooling data from the two placebo-controlled trials \[[@CR19]\] and two phase I trials \[[@CR13]\].

Methods {#Sec2}
=======

Safety and Pharmacokinetic Populations {#Sec3}
--------------------------------------

### Safety Population {#Sec4}

The safety population included patients from five studies: two identically designed, placebo-controlled studies conducted in the USA and Russia \[BUCF3001 (Clinicaltrials.gov identifier NCT01008410) and BUCF3002 (Clinicaltrials.gov identifier NCT01008423)\] \[[@CR19]\], an active-comparator (i.e., hydrocortisone foam) study conducted in Germany, Italy, and Israel (BUF-6/UCA) \[[@CR18]\], an active-comparator (i.e., budesonide enema) study conducted in Germany, Hungary, Lithuania, Latvia, Estonia, The Netherlands, and Israel (BUF-9/UCA) \[[@CR17]\], and an open-label extension study conducted in the USA for patients who completed BUCF3001 and BUCF3002 and had recurrent flares of UP or UPS \[BFPS3073 (ClinicalTrials.gov identifier NCT01349673)\].

In the two phase III, identically designed, multicenter, randomized, double-blind, placebo-controlled studies, patients were randomized 1:1 to receive budesonide foam 2 mg/25 mL or placebo twice daily for 2 weeks, then once daily for 4 weeks \[[@CR19]\]. Each study consisted of a screening phase, a run-in/stabilization phase of 4--7 days, a 6-week treatment phase, and a 2-week follow-up phase. Patients ≥18 years of age with active (endoscopy-confirmed) distal UP or UPS, extending ≥5 cm, but no further than 40 cm from the anal verge, and baseline Modified Mayo Disease Activity Index (MMDAI) scores between 5 and 10, inclusive, with subscale ratings ≥2 for endoscopic appearance and rectal bleeding were eligible for enrollment. Concomitant use of oral 5-ASA drugs at a stable dose up to 4.8 g/day was permitted. Key exclusion criteria included use of systemic, oral, topical, or rectal corticosteroids, or laxatives or enemas (other than 5-ASAs) during the previous 14 days.

In a phase III, multicenter, randomized, active-comparator (hydrocortisone foam), open-label study, patients were randomized to receive budesonide foam 2 mg/20 mL or hydrocortisone 100 mg/15 mL once daily for 8 weeks \[[@CR18]\]. Patients between 18 and 70 years of age with active (endoscopy- and histology-confirmed) UP or UPS and a disease activity index (DAI) ≥4 were eligible for enrollment. Concomitant use of oral 5-ASA drugs at a stable dose up to 2 g/day was permitted. Key exclusion criteria included use of corticosteroids within 1 month or immunomodulators within 3 months prior to baseline.

In a phase III, multicenter, randomized, double-blind, double-dummy, active-comparator (budesonide enema) study, patients were randomized to receive budesonide foam 2 mg/25 mL and placebo enema or budesonide enema 2 mg/100 mL and placebo foam once daily for 4 weeks \[[@CR17]\]. Patients between 18 and 70 years of age with active (endoscopy-, histology-, and negative stool culture-confirmed) UP or UPS, a DAI \> 4, and an endoscopic index ≥4 were eligible for enrollment. Concomitant use of 5-ASA drugs and long-term nonsteroidal antiinflammatory drug treatment were not permitted. Key exclusion criteria included use of oral/rectal corticosteroids within 1 month or immunomodulators within 3 months prior to baseline.

In a multicenter, open-label extension study (BFPS3073), patients who completed BUCF3001 and BUCF3002 were permitted to receive additional 6-week treatment cycles of budesonide foam for recurrent flares of UP or UPS. When a flare occurred, budesonide foam 2 mg was administered rectally twice daily for 2 weeks followed by 2 mg once-daily administration for 4 weeks.

### Pharmacokinetics Population {#Sec5}

The pharmacokinetics (PK) population included patients from four studies: two identically designed, placebo-controlled, phase III studies (BUCF3001 and BUCF3002) \[[@CR19]\] and two phase I studies \[single-dose (BUF-4/BIO) \[[@CR13]\], and multiple-dose (BUF-7/BIO)\]. In the single-dose, open-label, single-center, phase I study conducted in Austria, patients with active, mild-to-moderate UC, as defined by the DAI \[[@CR20]\], received a dose of ^99m^Tc-labeled budesonide foam 2 mg/20 mL \[[@CR13]\]. In the multiple-dose, open-label, single-center, phase I study conducted in Germany, healthy male volunteers received a single dose of budesonide foam 2 mg on day 1, followed by budesonide foam 2 mg twice daily from days 2 to 5.

Safety Assessments {#Sec6}
------------------

Safety assessments included periodic monitoring of adverse events (AEs), clinical laboratory tests \[including morning cortisol concentrations and adrenocorticotropic hormone (ACTH) challenge tests\], measurement of vital signs, and monitoring of concomitant medications. For studies that included an ACTH challenge test, patients were administered a 250-µg dose of cosyntropin between 8 am and 10 am, or approximately within 2--4 h of waking, via intramuscular injection. Blood for serum cortisol assessments was drawn immediately prior to cosyntropin administration (baseline) and at a 30-min time point after the challenge. Per protocol, adrenal insufficiency was defined as having a serum cortisol concentration of ≤18 μg/dL at 30 min following ACTH challenge.

Pharmacokinetic Bioanalysis {#Sec7}
---------------------------

Blood samples for pharmacokinetic assessments were collected, and plasma budesonide concentrations were determined using high-performance liquid chromatography (HPLC)-dual mass spectroscopy. The effect of budesonide foam on the hypothalamic--pituitary-adrenal (HPA) axis was assessed by evaluating correlations of plasma budesonide maximum concentration (*C*~max~) and area under the curve (AUC) values with results of the week-6 ACTH challenge in studies BUCF3001 and BUCF3002.

Statistical Analyses {#Sec8}
--------------------

The safety population was defined as any enrolled patient who received ≥1 dose of study medication. Demographic and baseline disease characteristics, exposure, and safety data were summarized using descriptive statistics. Two models were used for the population pharmacokinetic analysis: the traditional forward addition approach and the single-objective hybrid genetic algorithm \[SOHGA, DARWIN™ (Nuventra Pharma Sciences, Research Triangle Park, NC)\] \[[@CR21], [@CR22]\]. The traditional forward addition approach, which used a *p* value \<0.05 for a likelihood ratio test (LRT), was used in combination with diagnostic figures and consideration of biologic plausibility to add features to a trivial model (compartments, mixture models, lag time, covariates). The SOHGA utilizes user-defined criteria to provide a robust method for selecting population PK models, designed to result in a large model (*P* \< 0.05), convergence, a successful covariance step, and a successful correlation and condition number test. The two models were combined for a final forward addition/backward elimination process, using the LRT with forward addition and *P* \< 0.05 and backward elimination with *P* \< 0.01. The final model used for analysis was a one-compartment model with first-order absorption and an absorption lag time.

Results {#Sec9}
=======

Patients {#Sec10}
--------

The safety population for budesonide foam included 719 patients from five phase III trials, including two placebo-controlled trials, two active-controlled trials, and one open-label extension trial (Fig. [1](#Fig1){ref-type="fig"}). The safety population for placebo included 278 patients from two phase III placebo-controlled trials. The majority of patients in the placebo- and active-controlled studies (84.3 % of patients in the budesonide foam group and 86.3 % of patients in the placebo group) completed the studies.Fig. 1Patient disposition. The safety population for the budesonide foam group (*n* = 719) included the budesonide foam groups in the two placebo-controlled trials (*n* = 268) and two active-controlled trials (*n* = 387), and the placebo-crossover group (*n* = 64) in the open-label extension study. The safety population for the placebo group (*n* = 278) included patients from two placebo-controlled trials

Demographic and baseline characteristics were generally similar between groups (Table [1](#Tab1){ref-type="table"}). A greater percentage of patients in the budesonide foam group had mild disease severity compared with the placebo group (26.7 vs 12.2 %, respectively). In the overall budesonide foam treatment group, fewer patients used 5-ASAs at baseline compared with the placebo group (31.7 vs 55.4 %, respectively); this is because concomitant use of 5-ASAs was prohibited in one of the active-controlled studies. However, when only studies that allowed the use of 5-ASAs at baseline were considered in the analysis, a greater percentage of patients receiving budesonide foam versus those receiving placebo also reported using 5-ASAs at baseline (68.9 vs 55.4 %, respectively). The mean duration of drug exposure was 46.5 days \[standard deviation (SD), 40.1 days\] and 39.1 days (SD, 9.2 days) for budesonide foam and placebo groups, respectively. The total number of person-years of exposure was 91.2 in the budesonide foam group and 29.8 in the placebo group.Table 1Demographics and baseline characteristics (safety population)CharacteristicBudesonide foam (*n* = 719)Placebo (*n* = 278)Age (year), mean (SD)43.4 (13.3)41.6 (13.2)Sex \[*n* (%)\] Male342 (47.6)115 (41.4) Female377 (52.4)163 (58.6)Race \[*n* (%)\] White672 (93.5)257 (92.4) Black33 (4.6)13 (4.7) Other14 (1.9)8 (2.9)Body mass index (kg/m^2^), mean (SD)25.7 (4.9)^a^26.0 (5.1)Duration of disease (year), mean (SD)5.9 (7.3)4.4 (6.0)Extent of disease \[*n* (%)\] Proctitis^b^241 (33.5)81 (29.1) Proctosigmoiditis^c^475 (66.1)196 (70.5) Missing3 (0.4)1 (0.4)Severity of disease \[*n* (%)\]^d^ MMDAI score \< 44 (0.6)0 Mild192 (26.7)34 (12.2) Moderate505 (70.2)244 (87.8) Severe14 (1.9)0 Missing4 (0.6)0Baseline use of 5-ASA \[*n* (%)\]228 (31.7)154 (55.4)*5*-*ASA* 5-aminosalicylic acid, *CAI* clinical disease activity index, *DAI* disease activity index, *MMDAI* Modified Mayo Disease Activity Index^a^ *n* = 715^b^Proctitis was defined as disease limited to the rectum (up to \~15 cm from the anal verge)^c^Proctosigmoiditis was defined as disease limited to the rectum and sigmoid colon (up to \~40 cm from the anal verge)^d^Mild (MMDAI score 4--6); moderate (MMDAI score 7--10), and severe (MMDAI score 11--12) in BUCF3001 and BUCF3002. Assessment of disease severity in study BUF-6/UCA by DAI and in study BUF-9/UCA by CAI and DAI \[[@CR17], [@CR18]\]

In the current analysis, AEs were reported by 41.4 and 36.3 % of patients treated with budesonide foam and placebo, respectively (Table [2](#Tab2){ref-type="table"}). Most AEs were mild or moderate in intensity and occurred in a similar percentage of patients in both groups, 93.3 and 96.0 % of patients receiving budesonide foam or placebo, respectively. The most common AEs (reported by ≥2 % of patients) in the budesonide foam group were decreased blood cortisol concentrations, headache, abdominal pain, and nausea. Adverse events considered to be at least possibly related to study drug occurred in 15.6 and 5.8 % of patients in the budesonide foam and placebo groups, respectively.Table 2Summary of adverse events (safety population)Adverse event \[*n* (%)\]Budesonide foam (*n* = 719)Placebo (*n* = 278)Any AE298 (41.4)101 (36.3) Drug-related AE112 (15.6)16 (5.8) AE leading to discontinuation57 (7.9)12 (4.3) Serious AE^a^8 (1.1)3 (1.1)Most common AEs^b^ Decreased blood cortisol concentration66 (9.2)6 (2.2) Headache45 (6.3)7 (2.5) Abdominal pain26 (3.6)4 (1.4) Nausea18 (2.5)2 (0.7) Ulcerative proctitis06 (2.2)Glucocorticoid-related AEs Acne4 (0.6)0 Agitation1 (0.1)0 Depression4 (0.6)1 (0.4) Insomnia3 (0.4)1 (0.4) Sleep disorder1 (0.1)0 Weight increase2 (0.3)1 (0.4)*AE* adverse event, *SAE* serious adverse event, *UC* ulcerative colitis^a^SAEs reported in budesonide foam group were: UC in two patients (severe in one patient and moderate in one patient), severe abdominal pain, severe acute exanthematous pustulosis (only drug-related SAE observed), severe arterial thrombosis limb, moderate diarrhea, moderate hypersensitivity, and mild unstable angina in one patient each; in the placebo group: severe anemia, ectopic pregnancy of moderate severity, and moderate UC in one patient each^b^ ≥2 % of patients in any group

The most common AEs (≥5 patients) considered related to treatment with budesonide foam were decreased blood cortisol concentrations (6.1 %), adrenal insufficiency (1.8 %), headache (1.0 %), abdominal pain (0.8 %), and nausea (0.7 %). The incidence of glucocorticoid (noncortisol)-related AEs of interest was low and not different between budesonide foam and placebo. Adverse events leading to study discontinuation were observed in 7.9 and 4.3 % of patients in the budesonide foam and placebo groups, respectively. Serious AEs occurred in 8 (1.1 %) and 3 (1.1 %) patients in the budesonide foam and placebo groups, respectively; no deaths were reported during the studies.

Mean morning cortisol concentrations remained within normal limits in both treatment groups for the duration of treatment, with the majority of patients in each group maintaining total cortisol concentrations above the lower limit of normal (\>138 nmol/L; 83.0 vs 93.1 % for budesonide foam and placebo groups, respectively; Fig. [2](#Fig2){ref-type="fig"}). Although there was a slight decrease in mean morning cortisol concentrations at weeks 1 and 2 during twice-daily dosing in the budesonide foam group, the concentrations were similar to baseline values by week 4. Further, the majority of patients receiving budesonide foam or placebo also maintained normal responses to ACTH challenge at week 6 (86.1 vs 96.2 %, respectively; Table [3](#Tab3){ref-type="table"}).Fig. 2Mean morning cortisol concentrations up to 8 weeks for budesonide foam group and 6 weeks for placebo group. Data are from the randomized-controlled trials (placebo- and active-controlled trials). *Error bars* indicate standard deviations. Morning cortisol concentration results recorded as a threshold value rather than exact value were not imputed as data for the figureTable 3Total cortisol concentrations and normal response to ACTH challenge (randomized safety population)Parameter, *n*/*N* ^a^ (%)Budesonide foam (*n* = 655)^b^Placebo (*n* = 278)^b^Total cortisol \>5 µg/dL (138 nmol/L)^c^ Baseline622/638 (97.5)275/278 (98.9) Week 1224/263 (85.2)264/269 (98.1) Week 2315/366 (86.1)263/266 (98.9) Week 4539/565 (95.4)243/249 (97.6) Week 6211/224 (94.2)234/241 (97.1) Week 865/69 (94.2)--Normal response to ACTH challenge^d,e^ Baseline261/266 (98.1)275/278 (98.9) Week 6186/216 (86.1)226/235 (96.2)*ACTH* adrenocorticotropic hormone^a^Denominator *N* is the number of patients with a value at each given week during the study^b^Only patients in the four randomized studies were included^c^Lower limit of normal^d^The normal response to ACTH challenge, defined by protocol as a cortisol concentration of \> 18 µg/dL (500 nmol/L) at 30 min following ACTH challenge^e^Data based on patients in BUCF3001 and BUCF3002 studies

Pharmacokinetics {#Sec11}
----------------

Overall, 1296 observations were available from a total of 145 patients and healthy volunteers in the PK population: 12 patients with mild-to-moderate UC from a phase I, single-dose study, 18 healthy volunteers from a phase I multiple-dose study, and 115 patients with mild-to-moderate UP or UPS from two placebo-controlled phase III trials. Overall, the PK population was 58.6 % male and 87.6 % white, with a mean age of 42.3 years.

Plasma concentrations of budesonide were below the limit of quantitation (0.03 ng/mL) in 33 % of samples from patients in the two placebo-controlled phase III trials. Mean plasma budesonide concentrations in samples from patients with concentrations above the limit of quantitation were similar to those of samples from healthy volunteers in the phase I multiple-dose study.

The estimated mean *C*~max~ and mean AUC in the overall PK population were 0.57 ng/mL and 4.31 ng h/mL, respectively (Table [4](#Tab4){ref-type="table"}). There were no substantial differences between patients with UC and healthy volunteers for the PK parameters estimated. However, in the 115 patients with UC, there was a statistically significant effect of UC symptom severity on the elimination rate constant.Table 4Noncompartmental parameter estimatesParameter, mean (CV)Pharmacokinetic population (*N* = 145)Clearance/F (L/h)464 (640)Volume of distribution/F (L)2700 (274)Absorption lag time (h)0.149AUC (ng h/mL)4.31 (64)*C* ~max~ (ng/mL)0.573 (37)*AUC* area under the curve, *C* ~*max*~ maximum plasma concentration, *CV* coefficient of variation, *F* absolute bioavailability

ACTH challenge test results at week 6 were compared with estimates of plasma budesonide *C*~max~ and AUC values in combined data from BUCF3001 and BUCF3002. In this comparison, a negative correlation between ACTH challenge sensitivity, measured as the increase in serum cortisol level in response to ACTH challenge, and plasma budesonide *C*~max~ or AUC would be evidence of a biologically plausible association between budesonide plasma concentrations and adrenal suppression. However, no negative correlation between sensitivity to ACTH challenge and budesonide plasma *C*~max~ or AUC values was observed.

Discussion {#Sec12}
==========

In this integrated analysis of safety from five phase III trials, budesonide foam administered rectally for up to 8 weeks was shown, overall, to be safe for patients with mild-to-moderate UP or UPS, as treatment with budesonide foam was associated with a low incidence of AEs. Pooling of safety data for \>700 patients exposed to budesonide foam provided a robust assessment of the overall safety and allowed for a better review of potentially uncommon AEs in a larger patient population than was possible to assess from each individual study alone. These data represent a comprehensive report regarding the safety of budesonide foam for the treatment of patients with UP or UPS. Budesonide foam has previously been shown to be efficacious for the induction of remission in this patient population \[[@CR17], [@CR18], [@CR23]\].

The incidence and severity of AEs and severe AEs reported in this analysis were generally similar between budesonide foam and placebo groups \[[@CR18]\]. No clinically significant adrenal suppression with budesonide foam therapy was detected, confirming results from previous studies with rectal budesonide preparations that showed serum cortisol concentrations within normal range \[[@CR24], [@CR25]\]. These data are consistent with results observed with short-term administration of oral budesonide preparations \[[@CR26]--[@CR30]\]. This is likely because budesonide undergoes extensive (\~90 %) hepatic first-pass metabolism, forming metabolites with little or no activity \[[@CR31]--[@CR33]\]. The incidence of glucocorticoid (noncortisol)-related AEs, such as sleep changes, acne, and weight gain, were rare and were similar between budesonide foam and placebo groups; however, assessment of potential glucocorticoid effects was not prespecified in all study protocols. Serum cortisol concentrations had the greatest decrease during weeks 1 and 2, compared with weeks 4 and 6; this effect was likely driven by twice-daily dosing in weeks 1 and 2 in studies BUCF3001 and BUCF3002, followed by subsequent daily dosing for the last 4 weeks of these studies.

The population-based PK analysis demonstrated low systemic exposure of budesonide foam. Budesonide foam has a local-to-systemic exposure ratio of \>40,000 to 1, consistent with its local site of action in the distal colon. Increases in budesonide systemic exposure (*C*~max~ and AUC) did not correlate with diminished response to ACTH challenge. The majority of patients treated with budesonide foam or placebo had normal HPA function with the ACTH challenge test at week 6, findings driven by the BUCF3001 and BUCF3002 studies. These results suggest that exposure to rectally administered budesonide at the doses studied for up to 6--8 weeks does not have clinically relevant effects on the HPA axis.

A potential study limitation is that this analysis included data from studies with minor differences in disease severity, inclusion and exclusion criteria, and study duration. Also, whether concomitant use of 5-ASAs at baseline was permitted differed between the studies included in this analysis. In the overall study population, a greater percentage of patients receiving placebo used 5-ASAs at baseline; however, two studies did not permit concomitant use of 5-ASAs at baseline. When these two studies were excluded from analysis, the majority of patients receiving budesonide foam used 5-ASAs at baseline. It is unclear whether baseline use of 5-ASAs influenced the safety profile of budesonide foam. However, a subgroup analysis (BUCF3001 and BUCF3002 studies) evaluating the potential impact of oral 5-ASA use on the efficacy and safety of budesonide foam supports that baseline oral 5-ASA use does not impact the tolerability and safety profile of budesonide foam \[[@CR34]\].

Results of this integrated analysis demonstrated a short absorption lag time and a rapid absorption rate. A positive finding from this analysis was the lack of a relationship between presence of UP and UPS and PK parameters; however, the severity of disease symptoms was predictive of the elimination rate constant, with more severe symptoms predictive of decreased elimination. Comparisons of PK parameters between rectally administered budesonide foam and oral formulations of budesonide are limited by the lack of pharmacokinetic data from oral formulations available in patients with UP or UPS \[[@CR35]\].

The findings of this comprehensive safety analysis, together with published efficacy results, offer healthcare providers and patients an additional rectally administered therapeutic option for the induction of remission of UP and UPS. Budesonide foam has a low incidence of clinically relevant effects on the HPA axis as shown using ACTH challenge and has a favorable safety profile, most likely related to its minimal systemic exposure. While 5-ASA treatment remains first-line therapy for the induction of remission in patients with mild-to-moderate UP or UPS \[[@CR2], [@CR7], [@CR9], [@CR10]\], budesonide foam may be an efficacious and better-tolerated alternative to systemic corticosteroids for the treatment of mild-to-moderate UP or UPS. Indeed, orally administered budesonide MMX has been shown to have a favorable safety profile, with demonstrated efficacy for the induction of remission of mild-to-moderate UC \[[@CR27], [@CR28]\]. Availability of both oral and rectal formulations makes it possible for budesonide therapy to be integrated in the current treatment algorithm: as an option after 5-ASAs and before treatment with systemic corticosteroids \[[@CR36]\]. In conclusion, rectally administered budesonide foam had a low incidence of AEs in this integrated safety analysis and did not appear to adversely affect the HPA axis when used to treat patients with mild-to-moderate distal UC.
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